Pro-Dex, Inc. — Form 10-Q summary
Reporting period: The filing covers the three and nine months ended March 31, 2020 (the company’s fiscal third quarter and first nine months of fiscal 2020), with comparisons to the same periods in 2019. This differs from the request metadata’s “2019 Q3.” Financial amounts below are in millions unless noted.
Business context and financial performance
Pro-Dex designs and manufactures surgical drivers and shavers, primarily for medical-device customers, and also sells rotary air motors. Medical-device products accounted for 78% of quarterly sales and 76% of nine-month sales. Results benefited from initial shipments of a private-label thoracic driver and increased repair revenue.
| Metric | Three months ended March 31 | Nine months ended March 31 |
|---|---|---|
| Net sales | $8.508 vs. $6.854; up 24% | $23.710 vs. $20.168; up 18% |
| Gross profit / margin | $3.210 / 38%, vs. $2.263 / 33% | $8.855 / 37%, vs. $7.238 / 36% |
| Operating income | $1.704 vs. $0.897 | $4.864 vs. $3.818 |
| Net income | $1.213 vs. $0.732 | $3.567 vs. $3.260 |
| Diluted EPS | $0.30 vs. $0.17 | $0.88 vs. $0.75 |
| Comprehensive income (loss) | $(0.049) vs. $0.765 | $2.954 vs. $3.097 |
Quarterly gross-margin improvement reflected higher sales, better absorption of fixed manufacturing costs, and the launch of a higher-margin thoracic driver. Nine-month profit also benefited from higher repair revenue. Nine-month net income rose modestly despite a prior-year $0.356 million gain on an investment sale. A $1.262 million quarterly unrealized investment loss drove the quarterly comprehensive loss.
Cash flow, liquidity, and debt
- For the nine months, operating cash flow was $2.298 million, down from $3.085 million. Inventory increased $2.404 million, principally for thoracic-driver shipments and a planned customer product launch.
- Investing cash outflow was $2.253 million, including $1.827 million of investment purchases and $0.422 million of equipment purchases. Financing cash outflow was $3.409 million, primarily $2.977 million of share repurchases and $0.471 million of debt and lease principal payments.
- At March 31, cash and cash equivalents were $4.378 million, working capital was $16.140 million, and total assets were $28.228 million. Marketable equity securities totaled $4.430 million and had $1.162 million of net unrealized losses.
- Notes and capital leases payable totaled approximately $4.091 million on the balance sheet; the MBT term-loan balance was approximately $4.1 million, net of unamortized fees. The $2.0 million revolving facility was undrawn and extended to November 6, 2020. Management said available cash, receivables, and operating cash flow were expected to meet requirements for at least 12 months.
- Lease accounting adoption added approximately $3.3 million each to assets and liabilities at July 1, 2019. The March 31 balance sheet reports a $3.026 million right-of-use asset and $2.857 million noncurrent lease liability, with the current portion included in accrued expenses.
Material changes, outlook, and risks
- Thoracic-driver initial shipments totaled $1.5 million in the quarter. Repair revenue increased $1.2 million in the quarter and $4.1 million for the nine months, largely for the largest customer’s orthopedic handpiece. Medical-device sales excluding these growth areas faced declines at legacy customers and CMF distributors.
- At March 2020, backlog was approximately $14.8 million: $10.8 million was scheduled for delivery in fiscal Q4, including $2.3 million remaining on the initial thoracic-driver order. The company cautioned that some shipments could slip into fiscal Q1 2021. Management expected repair revenue in fiscal Q4 to be comparable to the March quarter; it gave no broader revenue or earnings guidance.
- COVID-19 had not materially affected third-quarter results, but customers had requested some shipment delays. Management cited potential future demand reductions, delayed or canceled orders, payment delays, supplier disruption, and workforce impacts. The company continued operating under an essential-business exemption, with remote work, staggered shifts, enhanced cleaning, and other precautions.
- Two customers represented 84% of nine-month sales; the largest represented 69%. At quarter-end, two customers accounted for 89% of gross receivables. This concentration increases exposure to customer demand, payment, and operating changes.
- The company repurchased 204,921 shares for $2.977 million during the nine months and had a new authorization to repurchase up to one million shares. Management said research, development, selling, and administrative spending was expected to continue increasing in the near term, with no assurance new products or customers would result.
- After quarter-end, the company received $1.360 million under a PPP loan on April 10, 2020, and repaid it on May 5, 2020 following further government guidance. The filing also reports $0.489 million of unrecognized tax benefits and describes routine legal proceedings, with no specific material proceeding identified.
Important facts for investors to verify
- Confirm the period: this is fiscal Q3 2020, ended March 31, 2020, despite the request metadata’s 2019 Q3 label.
- Track the largest customers’ order levels, payment behavior, and the concentration of sales and receivables.
- Verify shipment timing and conversion of the reported backlog, especially the thoracic-driver balance, and assess COVID-19 effects on elective procedures and supply continuity.
- Monitor inventory growth, operating cash conversion, cash needs, and the maturity and covenant terms of the bank facilities.
- Assess volatility and potential realized losses in the marketable-equity portfolio, including the reported related-party investment relationships.
- Review the source filing’s detailed financial statements and MD&A for any presentation or rounding differences when reconciling reported figures.